Cediranib

西地尼布

Report date: 2026/04/03 20:03:44
NME

Base Information

Drug NameCediranib
Drug Alias Namecediranib塞地拉尼cediranib maleateCediranib-maleateCediranibmaleate +[11] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionVascular endothelial growth factor receptor 3 antagonistsVascular endothelial growth factor receptor 1 antagonistsVascular endothelial growth factor receptor 2 antagonists
TargetsVascular endothelial growth factor receptor 1Vascular endothelial growth factor receptor 3Vascular endothelial growth factor receptor 2
Therapy Area/IndicationsUveal melanomaMetastatic breast cancerSkin Melanoma +[117] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[40] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPending
Originator CompaniesAstrazeneca Plc
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of LiverpoolUniversity Of OxfordAstrazeneca Plc +[6] 
Inactive CompaniesRadboud University Medical CenterUniversity College LondonThe University Of Manchester +[6] 
Active IndicationsMetastatic breast cancerSkin MelanomaSolid tumours +[37] 
Inactive IndicationsUveal melanomaOncocytic cell carcinoma of the thyroidHormone-Resistant Prostate Neoplasms +[80] 

Other Information

ATC CodeL01EK02
Related LinksWikipediaKEGG